Table 1

Demographic and Clinical Characteristics at Baseline

CharacteristicPlacebo (n = 138)Nesiritide (n = 141)
Age, yrs64.1 ± 11.363.6 ± 10.5
Male gender, n (%)108 (78)111 (79)
Race/ethnicity, n (%)
 White117 (85)115 (82)
 Black9 (7)10 (7)
 Hispanic10 (7)11 (8)
 Other2 (1)5 (4)
Weight, kg89.2 ± 21.786.9 ± 19.6
New York Heart Association functional class, n (%)
 I1 (1)0 (0)
 II71 (51)64 (45)
 III52 (38)62 (44)
 IV13 (9)14 (10)
Left ventricular ejection fraction, %30.1 ± 7.329.7 ± 7.5
BNP, pg/ml406 ± 511431 ± 615
N-terminal pro-BNP, pg/ml3026 ± 42242877 ± 4802
Medical history, n (%)
 Non–insulin-dependent diabetes mellitus43 (31)45 (32)
 Insulin-dependent diabetes mellitus26 (19)23 (16)
 Chronic obstructive pulmonary disease25 (18)25 (18)
 Other pulmonary disease17 (12)21 (15)
 Reactive precapillary pulmonary hypertension7 (5)5 (4)
 Mild liver disease5 (4)5 (4)
 Anemia24 (17)27 (19)
 Peripheral vascular disease30 (22)29 (21)
 Diabetic nephropathy8 (6)6 (4)
 Other chronic renal disease33 (25)28 (21)
Renal function
 Serum creatinine, mg/dl1.11 ± 0.441.07 ± 0.40
 Blood urea nitrogen, mg/dl22.4 ± 8.822.5 ± 11.3
 Glomerular filtration rate, ml/min/1.73 m277.6 ± 28.182.0 ± 30.3
Hemodynamics
 Mean systolic blood pressure, mm Hg120 ± 21122 ± 21
 Mean pulmonary artery pressure, mm Hg25.4 ± 8.825.6 ± 8.7

BNP = B-type natriuretic peptide.

  • Differences between placebo and nesiritide groups are all non-significant (analysis of variance continuous variables and chi-square for categorical variables).

  • As reported by the attending physician.